Genetic testing for warfarin dosing? Not yet ready for prime time

Pharmacotherapy. 2008 Feb;28(2):141-3. doi: 10.1592/phco.28.2.141.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Algorithms
  • Anticoagulants / administration & dosage*
  • Anticoagulants / adverse effects
  • Aryl Hydrocarbon Hydroxylases / genetics*
  • Cytochrome P-450 CYP2C9
  • Drug Dosage Calculations
  • Genotype
  • Humans
  • International Normalized Ratio
  • Mixed Function Oxygenases / genetics*
  • Pharmacogenetics
  • Vitamin K Epoxide Reductases
  • Warfarin / administration & dosage*
  • Warfarin / adverse effects

Substances

  • Anticoagulants
  • Warfarin
  • Mixed Function Oxygenases
  • CYP2C9 protein, human
  • Cytochrome P-450 CYP2C9
  • Aryl Hydrocarbon Hydroxylases
  • Vitamin K Epoxide Reductases